Vertex and Alios Begin Clinical Studies of Nucleotide Drug Candidates ALS-2200 and ALS-2158
December 09, 2011
Read More...

Alios BioPharma, Inc. and Versitech Ltd. Announce Exclusive Agreement
October 31, 2011
Read More...

Vertex and Alios BioPharma Announce Exclusive Worldwide Licensing Agreement
June 13, 2011
Read More...

Alios BioPharma Issued Broad U.S. Patent for Glyco-engineered Interferons
October 16, 2009
Read More...

Alios BioPharma, Inc. has appointed Plexxikon Founder and Chief Executive Officer K. Peter Hirth, Ph
August 13, 2009
Read More...

Alios BioPharma, Inc. Closes $32 Million Series A Financing
June 11, 2009
Read More...

Alios BioPharma, Inc. Completes First Closing of Series A Financing with Commitment of $24 MM from 3 Top-Tier Investors
February 12, 2009
Read More...

Dr. Lawrence Blatt presents at C21 Bio Ventures conference; May 21-22, 2008
May 23, 2008
Read More...

DEVELOPMENT OF NOVEL HYPERGLYGOSYLATED TYPE 1 INTERFERONS: A STRATEGY TO IMPROVE PK PERFORMANCE WITHOUT LOSS OF BIOLOGICAL POTENCY
May 16, 2008
Read More...

Alios BioPharma Licenses RNase L Activators from Cleveland Clinic for Antiviral and Anticancer Therapeutics -- Company Plans to Develop New Class of Broad Spectrum Drugs for the Treatment of Viral Diseases and Cancer --
November 20, 2007
Read More...